Supriya Lifescience Limited
All news and filings related to Supriya Lifescience Limited.
View all news & filings- Medium impact
Supriya Lifescience Files Petition with Supreme Court on Judicial Proceedings
Supriya Lifescience Limited filed a petition with the Supreme Court of India on October 8, 2026. This follows a previous order from the High Court. The matter is sub judice, and the company will provide further updates as they become available.
Read the summary - Low impact
Supriya Lifescience: Trading Window Closed Oct 1, 2026, for Q2/H1 FY27 Results
Supriya Lifescience Limited will close its trading window from October 1, 2026. This is in compliance with SEBI regulations and the company's insider trading code. The window will reopen 48 hours after the declaration of the unaudited financial results for the quarter and half year ending September 30, 2026.
Read the summary - Medium impact
Supriya Lifescience Limited's 18th AGM: All resolutions passed, including final dividend declaration
Supriya Lifescience Limited's 18th AGM on September 24, 2026, saw all resolutions passed. Key approvals included the FY26 financial statements and a final dividend of ₹1.00 per share. Directors Dr. Saloni Wagh and Ms. Shivani Wagh were re-appointed, and Cost Auditors' remuneration for FY27 was ratified.
Read the summary - Medium impact
Supriya Lifescience gets provisional release of 200kg Ketamine HCl consignment
Supriya Lifescience Limited's application for provisional release of 200 kg Ketamine Hydrochloride consignment has been allowed by the Hon'ble High Court of Bombay. The release is conditional upon a ₹72 lakh deposit within a week. Adjudication and criminal proceedings can continue.
Read the summary - Low impact
Supriya Lifescience Clarifies Absence of Segment Details in Financial Results Due to Technical Error
Supriya Lifescience Limited clarified the absence of segment details in its August 13, 2026 financial results, attributing it to a technical error. The company operates in a single segment: Pharmaceuticals. It has reaffirmed its commitment to SEBI compliance and accurate disclosures.
Read the summary - Low impact
Supriya Lifescience to Hold Investor Group Meeting on Sep 25
Supriya Lifescience Limited will hold a virtual investor group meeting on September 25, 2026. An investor presentation has been uploaded on the company's website and stock exchanges.
Read the summary - Low impact
Supriya Lifescience to Hold Investor Group Meeting on Sep 17, 2026
Supriya Lifescience Limited will hold a virtual investor group meeting on September 17, 2026. The company has also uploaded its investor presentation on its website and stock exchanges.
Read the summary - Low impact
Supriya Lifescience Announces 18th AGM on Sept 24, 2026; Annual Report Available Online
Supriya Lifescience Limited will hold its 18th Annual General Meeting on September 24, 2026, via VC/OAVM. The Annual Report for FY 2025-26 is available online for shareholders.
Read the summary - Low impact
Supriya Lifescience: GM Legal Case Status Unchanged, Awaiting Court Adjudication
Supriya Lifescience Limited's General Manager's legal case remains sub judice, awaiting court adjudication. No new developments or orders have been passed by the court. The company previously updated investors on August 14 and 18, 2026, and will continue to monitor and report material developments.
Read the summary - Low impact
Supriya Lifescience Announces 18th AGM on September 24, 2026
Supriya Lifescience Limited will hold its 18th Annual General Meeting on September 24, 2026, via VC/OAVM. The Notice of AGM and Annual Report for FY 2025-26 were dispatched on September 1, 2026. Remote e-voting will be open from September 21 to September 23, 2026. The cut-off date for voting eligibility is September 17, 2026.
Read the summary - Low impact
Supriya Lifescience Announces 18th AGM on Sept 24, 2026, Proposes Re. 1 Dividend
Supriya Lifescience will hold its 18th AGM on September 24, 2026, via VC/OAVM. The company proposes a final dividend of Re. 1 per share for FY26. The audited financials for FY26 and the Annual Report will be presented. Directors Dr. Saloni Satish Wagh and Ms. Shivani Satish Wagh are up for re-appointment.
Read the summary - Low impact
Supriya Lifescience Limited Announces 18th AGM on Sep 24, 2026
Supriya Lifescience Limited will hold its 18th Annual General Meeting (AGM) on September 24, 2026, at 3:00 p.m. IST via Video Conferencing (VC) / Other Audio Visual Means (OAVM). This announcement complies with SEBI regulations and MCA circulars.
Read the summary - Low impact
Supriya Lifescience Fixes Record Date for Final Dividend and AGM on Sep 4, 2026
Supriya Lifescience has set September 4, 2026, as the record date for its final dividend payment for FY 2025-26. The company's AGM is scheduled for September 24, 2026, where the final dividend of Re. 1.00 per equity share will be proposed for approval.
Read the summary - Low impact
Supriya Lifescience: Balasaheb Sawant Re-appointed Whole Time Director
Supriya Lifescience Limited announced that Mr. Balasaheb Sawant has been re-appointed as Whole Time Director and Key Managerial Personnel for a three-year term from May 26, 2026, to May 25, 2029. The re-appointment was passed as a special resolution via postal ballot with an overwhelming majority. The voting concluded on August 21, 2026.
Read the summary - Medium impact
Supriya Lifescience Q1 FY27 Earnings Call Transcript Released
Supriya Lifescience reported Q1 FY27 revenue of ₹190 crores, up 31% YoY. EBITDA was ₹47 crores, down 8.1%, with margins at 25% due to temporary water and power cost issues. The company reiterated its FY27 revenue target of ₹1,000 crores and EBITDA margin guidance of 33-35%. New product launches and the Patalganga facility development are progressing.
Read the summary - Low impact
Supriya Lifescience Q1FY27 Earnings Call Audio Recording Available
Supriya Lifescience released the audio recording of its earnings call held on August 14, 2026. The call discussed the financial and operational performance for the quarter ended June 30, 2026. The recording is available on the company's website.
Read the summary - Low impact
Supriya Lifescience Publishes Q1 FY27 Newspaper Advertisement for Unaudited Financial Results
Supriya Lifescience Limited published a newspaper advertisement on August 14, 2026, containing extract of Unaudited Financial Results for the quarter ended June 30, 2026. This filing was made as per SEBI regulations.
Read the summary - Medium impact
Supriya Lifescience Q1 FY27 Revenue Jumps 31% YoY to ₹189.75 Crore
Supriya Lifescience reported Q1 FY27 revenue of ₹189.75 crore, a 31% YoY increase. EBITDA was ₹47.46 crore, and PAT was ₹24.04 crore. The company plans to launch new products in Anesthetic and ADHD segments.
Read the summary - Low impact
Supriya Lifescience Schedules Earnings Call for Q1 FY27 Results on August 14, 2026
Supriya Lifescience will host an earnings call on August 14, 2026, at 11:00 AM IST to discuss Q1 FY27 results. Key management, including the Executive Chairman and Managing Director, will participate.
Read the summary - Low impact
Supriya Lifescience Publishes Newspaper Clipping for Postal Ballot Notice
Supriya Lifescience Limited has published its Postal Ballot Notice in Financial Express and Loksatta. E-voting will be open from July 23, 2026, to August 21, 2026. The key resolution concerns the re-appointment of Mr. Balasaheb Sawant as Whole Time Director for a three-year term.
Read the summary - Low impact
Supriya Lifescience Seeks Shareholder Approval for Mr. Balasaheb Sawant's Re-appointment
Supriya Lifescience is seeking shareholder approval to re-appoint Mr. Balasaheb Sawant as Whole Time Director for a three-year term from May 26, 2026, to May 25, 2029. The voting will take place via postal ballot and e-voting from July 23 to August 21, 2026. Mr. Sawant's remuneration is proposed at ₹8.78 lakh per month.
Read the summary - Low impact
Supriya Lifescience Receives SEBI Compliance Certificate for Q1 FY27
Supriya Lifescience Limited received a compliance certificate for Q1 FY27 from its Registrar and Share Transfer Agent, MUFG Intime India Private Limited. The certificate confirms adherence to SEBI (Depositories and Participants) Regulations, 2018, regarding the processing and dematerialization of securities.
Read the summary - Medium impact
Supriya Lifescience Personnel Under Investigation by Customs Dept.
Supriya Lifescience personnel, Mr. Sreekant Sreedharan, General Manager, is under investigation by the Customs Department for an alleged procedural lapse in an export transaction. He is in judicial custody until July 17, 2026. The company anticipates no material impact on its operations or finances.
Read the summary - Low impact
Supriya Lifescience: Promoter Group Confirms No Share Encumbrance in FY26
Supriya Lifescience Limited's promoter and promoter group confirmed no share encumbrance for FY26 under SEBI Takeover Regulations. Key entities involved include Satish Waman Wagh and several group companies.
Read the summary - Medium impact
Supriya Lifescience: Final Dividend of ₹1.00 per Share for FY26 Recommended
Supriya Lifescience recommended a final dividend of ₹1.00 per share for FY26. The dividend payment is subject to shareholder approval at the AGM. Tax will be deducted at source for both resident and non-resident shareholders, with specific documentation required for beneficial tax rates. Shareholders must update details by July 15, 2026.
Read the summary - Low impact
Supriya Lifescience Limited Announces Trading Window Closure from July 1, 2026
Supriya Lifescience Limited will close its trading window from July 1, 2026. This closure is in accordance with SEBI regulations and the company's insider trading code. The window will reopen 48 hours after the declaration of unaudited financial results for the quarter ending June 30, 2026. The date for the board meeting to approve these results will be announced later.
Read the summary - Low impact
Supriya Lifescience to Meet Kotak PCG Clients on June 18, 2026
Supriya Lifescience Limited will hold a virtual group meeting with Kotak PCG Clients on June 18, 2026. An investor presentation has been uploaded to the company's website and stock exchanges.
Read the summary - High impact
Supriya Lifescience Releases Q4 FY26 Earnings Call Transcript, Highlights USFDA Approval
Supriya Lifescience reported FY26 revenue of ₹828 crores (up 18.9% YoY) and EBITDA of ₹294 crores (35.5% margin). Q4 FY26 revenue was ₹277 crores (up 50% YoY). The company received USFDA EIR with VAI classification for its Lote facility. It reiterated FY27 revenue guidance of ₹1,000 crores and EBITDA margin of 33-35%. Patalganga facility Phase 1 capex is ₹200 crores.
Read the summary - Low impact
Supriya Lifescience: Earnings Call Audio Recording Available Online
Supriya Lifescience Limited has made the audio recording of its May 28, 2026, earnings call available online. The call discussed the company's operational and financial performance for the quarter and year ended March 31, 2026.
Read the summary - Low impact
Supriya Lifescience Publishes Audited Financial Results for FY26 in Newspapers
Supriya Lifescience Limited announced its audited financial results for the quarter and year ended March 31, 2026. Key figures for the quarter include Total Income of ₹11,008 crore and Profit After Tax of ₹1,621 crore. For the full year, Total Income was ₹56,750 crore and Profit After Tax was ₹6,892 crore. The results were published in Financial Express and Loksatta on May 28, 2026.
Read the summary - High impact
Supriya Lifescience Q4 FY26 Revenue Surges 50% YoY to ₹276.53 Crore
Supriya Lifescience reported Q4 FY26 revenue of ₹276.53 crore, a 50.2% YoY increase. FY26 revenue reached ₹827.87 crore, up 18.9% YoY. PAT for Q4 FY26 was ₹74.23 crore and for FY26 was ₹209.12 crore. The anesthetic segment drove growth, contributing 54% of FY26 revenues.
Read the summary - High impact
Supriya Lifescience Q4 FY26 Investor Presentation: Revenue Up 50% YoY to ₹2,765 Crore
Supriya Lifescience reported Q4 FY26 revenue of ₹2,765.3 million, a 50.2% YoY increase. Full-year FY26 revenue reached ₹8,278.7 million, up 18.9% YoY. Q4 FY26 PAT was ₹742.3 million (up 47.4% YoY), and FY26 PAT was ₹2,091.2 million (up 11.3% YoY). The company highlighted export strength and R&D focus.
Read the summary - Medium impact
Supriya Lifescience Recommends Final Dividend of ₹1 Per Share
Supriya Lifescience's Board approved audited financial results for FY26. The company recommended a final dividend of ₹1 per share. Full-year revenue was ₹8,278.75 crore, with a profit after tax of ₹2,091.20 crore. The Board Meeting was held on May 27, 2026.
Read the summary - Low impact
Supriya Lifescience Schedules Earnings Call for Q4 FY26 Results on May 28
Supriya Lifescience will host an earnings call on May 28, 2026, at 11:00 AM IST to discuss Q4 and FY26 financial results. Management, including the Executive Chairman and CFO, will participate.
Read the summary - Medium impact
Supriya Lifescience's USFDA inspection concludes with one minor observation, classified as VAI.
Supriya Lifescience Limited's manufacturing facility in Lote, Maharashtra, underwent a USFDA inspection from February 2-6, 2026. The inspection resulted in one minor observation and concluded with a "Voluntary Action Indicated (VAI)" classification, indicating successful completion.
Read the summary - Low impact
Supriya Lifescience Shareholders Approve Director Appointments via Postal Ballot
Supriya Lifescience's shareholders have approved the appointment of Mr. Manish Panchal and Mr. Kothandaraman Hari as Non-Executive Independent Directors. Dr. Neelam Arora was re-appointed for a second term. All appointments are for five years, effective from February 9, 2026, and March 25, 2026, respectively. The resolutions passed with a significant majority.
Read the summary - Low impact
Supriya Lifescience Files SEBI Compliance Certificate for Q4FY26
Supriya Lifescience Limited submitted a compliance certificate for the quarter ended March 31, 2026. The certificate, issued by MUFG Intime India, confirms adherence to SEBI (Depositories and Participants) Regulations, 2018 regarding dematerialization and listing of securities.
Read the summary - Low impact
Supriya Lifescience Closes Trading Window from April 1, 2026 for Audited Financial Results
Supriya Lifescience Limited will close its trading window from April 1, 2026, until 48 hours after the declaration of audited financial results for the quarter and year ending March 31, 2026. The date of the board meeting for results declaration will be intimated later.
Read the summary - Low impact
Supriya Lifescience: Independent Directors Dinesh Modi and Dileep Jain Complete Tenure
Supriya Lifescience Limited announced that Independent Directors Mr. Dinesh Navnitlal Modi and Mr. Dileep Kumar Jain completed their five-year tenures on March 24, 2026. The board conveyed appreciation for their contributions. Committees were reconstituted on February 09, 2026.
Read the summary - Low impact
Supriya Lifescience Clarifies Absence of Segment Details in Financial Results Due to Technical Error
Supriya Lifescience Limited clarified that the absence of segment details in its February 09, 2026 financial results was due to a technical error. The company operates in a single segment, Pharmaceuticals, and has expressed regret for the inadvertent omission.
Read the summary - Low impact
Supriya Lifescience Publishes Newspaper Clipping for Postal Ballot Notice
Supriya Lifescience Limited published its Postal Ballot Notice in Financial Express and Loksatta. Members will vote on the appointment of Manish Panchal and Kolhandaraman Hari as Independent Directors, and the re-appointment of Neelam Arora. Remote e-voting is open from March 11 to April 10, 2026.
Read the summary - Low impact
Supriya Lifescience Seeks Shareholder Approval for Director Appointments via Postal Ballot
Supriya Lifescience is seeking shareholder approval via postal ballot for the appointment of Mr. Manish Panchal and Mr. Kothandaraman Hari as Independent Directors from February 9, 2026, to February 8, 2031. Dr. Neelam Arora's re-appointment is also proposed from March 25, 2026, to March 24, 2031. E-voting will be open from March 11, 2026, to April 10, 2026.
Read the summary - Medium impact
Supriya Lifescience Q3 FY26 Earnings Call Transcript Released
Supriya Lifescience reported Q3 FY26 revenue of ₹206 crore, up 11% YoY, with EBITDA at ₹72 crore and PAT at ₹50 crore. The company reaffirmed its guidance of ~20% annual revenue growth and 33-35% EBITDA margins, targeting ₹1,000 crore revenue by FY27. The Ambernath facility will be capitalized in Q4 FY26.
Read the summary - Low impact
Supriya Lifescience Releases Earnings Call Audio Recording for Q3 FY26
Supriya Lifescience Limited has released the audio recording of its earnings call held on February 10, 2026. The call discussed the operational and financial performance for the quarter and nine months ended December 31, 2025. The recording is available on the company's website.
Read the summary - Medium impact
Supriya Lifescience Q3 FY26 Revenue at ₹206.44 Crore, Net Profit ₹49.68 Crore
Supriya Lifescience reported Q3 FY26 revenue of ₹206.44 crore and net profit of ₹49.68 crore. For the nine months ended December 31, 2025, revenue was ₹551.35 crore and net profit was ₹134.89 crore. The results were approved by the board on February 09, 2026.
Read the summary - Medium impact
Supriya Lifescience Q3 FY26 Revenue Jumps 11.2% YoY to ₹206.44 Cr
Supriya Lifescience reported Q3 FY26 consolidated revenue of ₹206.44 crore, an 11.2% YoY increase. EBITDA was ₹72.08 crore and PAT was ₹49.68 crore. The anesthetic segment drove growth, with Latin America showing significant market share increase. Capacity utilization improved to 76%. The Ambernath formulation facility is set to launch in Q4 FY26.
Read the summary - Medium impact
Supriya Lifescience Q3FY26 Results: Revenue Up 11.2% YoY to ₹2,064.4 Cr, PAT ₹496.8 Cr
Supriya Lifescience reported Q3 FY26 revenue of ₹2,064.4 crore, up 11.2% YoY. PAT was ₹496.8 crore, a 6.2% increase. For 9M FY26, revenue reached ₹5,513.5 crore. The company has secured a 10-year CMO contract with a European firm for exclusive API supply, expected to generate ₹60 crore annually from FY27. Manufacturing capacity has been enhanced by over 55%.
Read the summary - Medium impact
Supriya Lifescience Appoints Manish Panchal, Kothandaraman Hari as Independent Directors; Reappoints Dr. Neelam Arora
Supriya Lifescience Limited's Board approved unaudited financial results for Q3 FY26 and appointed/reappointed directors. Dr. Neelam Arora was reappointed as Independent Director for 5 years from March 25, 2026. Manish Panchal and Kothandaraman Hari were appointed as Independent Directors from February 09, 2026. Q3 FY26 revenue was ₹206.44 crore, with net profit at ₹49.67 crore.
Read the summary - Medium impact
Supriya Lifescience Appoints Two Independent Directors, Reappoints One; Approves Q3 FY26 Results
Supriya Lifescience approved Q3 FY26 results with revenue at ₹2,064.40 crore and PAT at ₹496.75 crore. Dr. Neelam Yashpal Arora was re-appointed as Independent Director from March 25, 2026. Mr. Manish Panchal and Mr. Kothandaraman Hari were appointed as Independent Directors from February 09, 2026.
Read the summary - Medium impact
Supriya Lifescience Appoints Two New Independent Directors, Reappoints One
Supriya Lifescience's Board approved Q3 FY26 unaudited results. Revenue from operations for the quarter was ₹2,064.40 million, and profit after tax was ₹496.75 million. The company re-appointed Dr. Neelam Yashpal Arora as Independent Director and appointed Mr. Manish Panchal and Mr. Kothandaraman Hari as Additional Independent Directors.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio